Dose Escalation Study of ARQ 621 in Adult Patients With Metastatic Solid Tumors and Hematologic Malignancies

Completed · Phase 1

Conditions studied: Metastatic Solid Tumors, Refractory/Relapsed Hematologic Malignancies

In brief

This is an open-label, dose escalation study of intravenous ARQ 621 administered to patients with late-stage solid tumors or hematologic malignancies.

Key facts

Study ID

NCT00825487

Run by

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)

People needed

50

Starts

2009-08-01

Expected to finish

2011-09-01

Last updated by the study team

2011-10-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Signed written informed consent must be obtained and documented according to International Conference on Harmonisation (ICH)- Good Clinical Practice (GCP), the local regulatory requirements, and permission to use private health information in accordance with the Health Insurance Portability and Accountability Act (HIPPA) prior to study-specific screening procedures
• A histologically or cytologically confirmed metastatic solid tumor or refractory/relapsed hematologic malignancy
• Have a life expectancy of at least 12 weeks
• ≥18 years of age
• Measurable disease as defined by:
• Solid Tumors: Response Evaluation Criteria in Solid Tumors
• Multiple Myeloma (MM): International Uniform Response Criteria, at least one of the following:
• Monoclonal protein in the plasma of ≥0.5 g/dL
• Monoclonal protein in the urine of ≥0.2 g/24 hr urine collection
• Serum immunoglobulin free light chain (FLC) ≥100 mg/L (10 mg/dL) and abnormal serum immunoglobulin kappa to lambda FLC ratio
• Malignant Lymphoma (ML): International Working Group Response Criteria
• At least one site of disease ≥2 cm in longest diameter (a lesion ≥1 cm can be considered if PET positive)
• Chronic Lymphocytic Leukemia (CLL): NCI Working Group Guidelines
• Lymphocytosis (5 x 10\^9 /L) with B-cell marker (CD19, CD20,CD23) + CD5
• High-risk characteristics (hemoglobin <10g/dL OR platelets <100 x 10\^9 /L)
• Acute Myelogenous Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL): only patients with bone marrow or peripheral blast count of ≥20%
• Acute Promyelocytic Leukemia (APML): patients must be refractory to all-trans retinoic acid (ATRA) and arsenic trioxide
• Chronic Myelogenous Leukemia (CML): patients in blast crisis (bone marrow or peripheral blast count ≥20%) may be included if refractory to prior therapy and to any therapy the investigators deems of higher priority (for example, BCR-ABL inhibitors such as imatinib mesylate [Gleevec], nilotinib [Tasigna], or dasatinib [Sprycel])
• ECOG performance status ≤2
• Male or female patients of child-producing potential must agree to use contraception or avoidance of pregnancy measures during the study and for 30 days after the last ARQ 621 dose
• Females of childbearing potential must have a negative serum pregnancy test
• Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 × upper limit of normal (ULN) or ≤5.0 × ULN with metastatic liver disease
• Hemoglobin (Hgb) ≥10 g/dL (except in cases considered related to hematologic malignancy)
• Total bilirubin ≤1.5 × ULN
• Creatinine ≤1.5 x ULN (≤2.0 x ULN in cases considered related to multiple myeloma)

You may not qualify if…

• Anti-cancer chemotherapy, radiotherapy, immunotherapy, or investigational agents within four weeks of the first dose
• In cases of hematologic malignancies, 4-week recovery from prior anticancer treatment is not required, however the patient must recover from prior treatment-related non-hematological toxicities to grade 2 or less
• When required for supportive care corticosteroids or hydroxyurea may be used
• Surgery within four weeks prior to the first dose
• Known untreated brain metastases or leptomeningeal disease
• Patients with solid tumors who were treated for brain metastases and who have shown stable disease for at least 8 weeks prior to enrollment will be allowed
• Pregnant or breastfeeding
• Uncontrolled concurrent illness including, but not limited to ongoing or active symptomatic infection requiring systemic therapy, clinically significant non-healing or healing wounds, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection or psychiatric illness/social situations that would limit compliance with study requirements
• Patients having a history of Thrombotic thrombocytopenic purpura (TTP) or Hemolytic-uremic syndrome (HUS) or HUS spectrum will be excluded from the study

Where it is running

• Translational Genomics Institute — Phoenix, Arizona, United States
• Premiere Oncology — Santa Monica, California, United States
• Study site — Boston, Massachusetts, United States
• Nevada Cancer Institute — Las Vegas, Nevada, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.